Develops and manufactures advanced medical technology for cancer and neurological conditions. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
No real growth (3% a year). Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 1.1× for every dollar of annual revenue.
No analyst target is on record for this company.
The stock trades 59% below its peak. The market has trimmed its expectations for the company.
It pays out $0.26 per share each year — regular cash for whoever holds the stock.
A loss of $53.3M against $1.7B in annual sales. And on top of that, sales fell from the year before.
Since the drop from its peak, buyer appetite hasn’t come back.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.